Replimune (REPL) Long-Term Debt Issuances (2019 - 2023)

Replimune (REPL) posted Long-Term Debt Issuances of -$1.8 million for Q1 2023, down 620.0% sequentially from $355000.0 in Q4 2019.

Analysis

Replimune (REPL) Long-Term Debt Issuances (2019 - 2023) Analysis & Trends

Replimune has reported Long-Term Debt Issuances for 2 years, with the latest figure at -$1.8 million in Q1 2023.

Quarterly Long-Term Debt Issuances changed N/A year-over-year to -$1.8 million in Q1 2023, while the trailing twelve-month figure through Mar 2025 was -$1.8 million (changed 0.0% YoY) and the FY2026 annual result came in at $35.0 million, changed N/A from the prior year.
Long-Term Debt Issuances fell to -$1.8 million in Q1 2023 per REPL's latest filing, from $355000.0 in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $355000.0 in Q4 2019 and troughed at -$1.8 million in Q1 2023.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	-
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	-
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-
10	Replimune	1.46 Bn	1.46 Bn	-	-

Historic Data

Download Data